Committed to Research and Innovation

Thank you for your interest in a clinical research study to further evaluate the safety and efficacy performance of OTX-TIC for the treatment of glaucoma and ocular hypertension. OTX-TIC is an investigational drug which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).



  • Must be at least 18 years old
  • Must be diagnosed with ocular hypertension or open-angle glaucoma in the study eye
  • Must be willing to comply with all medication restrictions
  • Must not be participating in any other investigational studies
  • Must be able to visit your doctor’s office 10 times over the 6 month treatment period and includes 2 screening appointments; however additional visits may be required.


  • Established glaucoma and ocular hypertension patient population
  • Established Investigational Review Board (IRB)
  • Established and effective patient enrollment capabilities
  • Dedicated personnel and established infrastructure for clinical trial execution
  • OTX-TIC Phase 2 Clinical Trial Information:

If you meet either of the considerations listed above and want to be contacted regarding participation, as a participant or a site in the trial, please click here.

Other Questions? Please email

Travoprost Intracameral Implant (OTX-TIC)

Ocular Therapeutix is now evaluating, a new investigational intracameral implant containing travoprost (OTX-TIC) for the treatment of glaucoma or ocular hypertension in place of eye drops.1 OTX-TIC (travoprost intracameral implant) may deliver a constant dose of travoprost, which is a commonly used topical medication that can help reduce the pressure within the eye.2

This investigational implant may allow you to receive a steady dose of the therapy for the desired duration of therapy. Once placed in the eye, the intracameral implant has been designed to soften and break down over time while delivering medication, and then eventually dissolve over time, without the need for removal.3


Current treatment for Glaucoma and Ocular Hypertension

Although Glaucoma cannot be cured, it can be successfully controlled in most cases with laser therapy, surgery, or topical medication such as eye drops. The most common treatment for Glaucoma and Ocular Hypertension is the use of medicated eye drops. Your doctor may prescribe you more than one medicated eye drop to treat your condition. These drops must be taken every day and administered multiple times per day. Just like any other medication, it is important to follow your eye drop regimen regularly as prescribed by your doctor.4

Although drops are an effective treatment for helping to control and lower intraocular pressure, they may have limitations such as:4

  • Sometimes difficult to get into the eye correctly, with some of the medicine flowing out of the eye
  • Missed doses of the medication because of difficulty remembering to use multiple drops throughout the day

Due to the potential limitations of these drops, Ocular Therapeutix has developed OTX-TIC, which may have some potential advantage over topical drops that may include:

  • Delivering travoprost continuously over a period of time


Glaucoma affects 2 million people over 40 years of age in the United States alone

Glaucoma and Ocular Hypertension Overview

It is estimated that Glaucoma affects more than 2 million people over 40 years of age in the United States alone.5 Glaucoma is an eye disease in which the pressure within the eye becomes too high and causes damage to the optic nerve. This damage is irreversible and if left untreated can lead to blindness.6

Glaucoma can develop slowly, and there are virtually no symptoms. Because of the slow progression of the Glaucoma, you may not be aware of the gradual loss of sight until late in the disease when your vision has been affected.6

Ocular Hypertension is when the pressure inside the eye, also known as intraocular pressure or IOP, is higher than normal. In people with Ocular Hypertension, the optic nerve appears normal and without damage. Ocular Hypertension could lead to Glaucoma if not monitored closely by your doctor.7 As you age, intraocular pressure tends to gradually increase, just as glaucoma becomes more common as you get older.8

References: 1. A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT). identifier: NCT05335122. Updated April 19, 2022. Accessed May 13, 2022. 2. TRAVATAN Z® [package insert]. East Hanover, NJ: Novartis; 2020. 3. Goldberg D, et al. Hydrogel-based, Sustained-release Intracameral Travoprost Implant for Glaucoma Therapy: A Phase 1 Clinical Trial. Presented at the American Academy of Ophthalmology. New Orleans, LA. November 12-15, 2021. 4. Stein JD, et al. JAMA. 2021;325(2):164-174. 5. Gupta P, et al. Invest Ophthalmol Vis Sci. 2016;57(6):2905–2913. 6. Gupta D, et al. Am Fam Physician. 2016;15;93(8):668-74. 7. Kass MA, et al. Arch Ophthalmol. 2002;120: 701–713. 8. Shaikh Y, et al. Am J Ophthalmol. 2014;158(6):1121–1129.e1.